[First line durvalumab and tremelimumab in combination with chemotherapy for non-oncogene addicted metastatic non-small cell lung cancer (NSCLC)]

Bull Cancer. 2023 Nov;110(11):1094-1096. doi: 10.1016/j.bulcan.2023.08.006. Epub 2023 Sep 25.

[Article in French]

Authors

Marie Porte¹, Thomas Pierret²

Affiliations

¹ CHU de Nantes, hôpital Laennec, service d'oncologie, boulevard Professeur Jacques-Monod, 44800 Saint-Herblain, France.
² Hôpital Louis-Pradel, hospices civils de Lyon, service de pneumologie, 59, boulevard Pinel, 69667 Bron, France. Electronic address: thomas.pierret@chu-lyon.fr.

PMID: 37758567
DOI: 10.1016/j.bulcan.2023.08.006

No abstract available

Keywords: Cancer bronchique non à petites cellules; Chemotherapy; Chimiothérapie; Durvalumab; Non-small cell lung cancer; PDL1; Tremelimumab.

Publication types

Letter

MeSH terms

Antibodies, Monoclonal / therapeutic use
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Carcinoma, Non-Small-Cell Lung* / drug therapy
Carcinoma, Non-Small-Cell Lung* / pathology
Humans
Lung Neoplasms* / drug therapy
Lung Neoplasms* / pathology

Substances

durvalumab
tremelimumab
Antibodies, Monoclonal